Almirall, S.A. (ALM.MC)
| Previous Close | 8.51 |
| Open | 8.55 |
| Bid | 8.67 x 0 |
| Ask | 8.70 x 0 |
| Day's Range | 8.48 - 8.73 |
| 52 Week Range | 7.85 - 10.04 |
| Volume | |
| Avg. Volume | 114,567 |
| Market Cap | 1.861B |
| Beta (5Y Monthly) | 0.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.19 |
| Earnings Date | Feb 17, 2025 - Feb 21, 2025 |
| Forward Dividend & Yield | 0.18 (2.16%) |
| Ex-Dividend Date | May 17, 2024 |
| 1y Target Est | 11.79 |
GlobeNewswireEloxx Pharmaceuticals Announces Key Corporate Accomplishments
Data from Eloxx’s proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New protein analyses confirm production of both collagen alpha 4 and collagen alpha 5 in patients post treatment with ELX-02 Results justify the need to conduct a larger clinical trial of ELX-02 in NMAS to confirm clinical benefit U.S. Food and Drug Administration (FDA) allows for continued dosing of subject
Business WireAlmirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth
BARCELONA, Spain, November 11, 2024--Almirall, S.A. (ALM), a global biopharmaceutical company based in Barcelona, today announced its year to date financial results at the third quarter of 2024. Almirall continued to deliver strong sales growth in the first nine months of 2024 which were driven by the dermatology business, and especially the biologics portfolio in Europe. Net Sales increased by 7.9% YoY to a total of €727.6 MM, EBITDA was €142.2 MM (increase of 2.9% YoY) driven by higher sales g
